Market-View-Feature-Image

View on market: Stay Cautious, be with quality business:

Stocks in Asia fell Tuesday amid concerns on the impact on growth due to interest rate hikes by central banks and the surge in crude oil prices to $118 per barrel after the European Union backed a push to ban some Russian oil. Equities in Japan, Korea and Australia declined while Hong Kong futures fell. U.S. contracts rose. American markets were shut Monday for the Memorial Day holiday.
The Singapore-traded SGX Nifty, an early barometer of India’s benchmark Nifty 50, fell 0.14% to 16,623 points as of 6:20 am. India’s GDP data for quarter-ended March and estimate for FY22, fiscal deficit data and core output data for April are scheduled to be released today. European bonds fell as German inflation hit a record. The dollar rose slightly. U.S. President Joe Biden will hold a rare Oval office meeting on Tuesday with Fed Chair Jerome Powell amid rising inflation and ahead of US payroll numbers later this week. Elsewhere, Bitcoin was back above $31,000.

Economic Calendar:

  • INR: Trade Balance on 2nd June 2022.
  • INR: GDP Quartely on 31st May 2022.
  • USD: CB Consumer confidence 31st May, 2022.
  • USD: ADP Non Payroll Job Data 1st June, 2022.

Earnings Today: PTC India

Q4Fy22 Earning:

LIC Q4 FY22 (Consolidated, YoY) Revenue up 12% at Rs 2,12,230 crore Vs 1,90,099 crore EBITDA at Rs 2,396 crore Vs Rs 2,921 crore, down 18% EBITDA margins at 1.13% vs 1.54% Net profit down 17% of Rs 2,409 crore Vs Rs 2,917 crore EPS at Rs 3.81 vs Rs 4.61 Recommended dividend of Rs 1.5 per share of face value Rs 10 each

Sun Pharmaceuticals Q4 FY22 (Consolidated, YoY) Revenue up 11% at Rs 9,447 crore Vs Rs 8,523 crore (Bloomberg estimate: Rs 9,576 crore) EBITDA up 6% to Rs 2,179 crore from Rs 2,059 crore (Bloomberg estimate: Rs 2,544 crore) EBITDA margins at 23.1% Vs 24.2% (Bloomberg estimate: 26.6%) Net loss of Rs 2,277 crore.

Aurobindo Pharma Q4 FY22 (Consolidated, YoY) Revenue down 3% at Rs 5,809 crore Vs Rs 6,002 crore (Bloomberg estimate: Rs 5,901 crore) EBITDA down 24% to Rs 974 crore from Rs 1,275 crore (Bloomberg estimate: Rs 1,029 crore) EBITDA margins at 16.8% Vs 21.2% (Bloomberg estimate: 17.4%) Net profit down 28% to Rs 576 crore.

Jindal Steel and Power Q4 FY22 (Consolidated, YoY) Revenue up 35% at Rs 14,339.49 crore Vs Rs 10,593.72 crore (Bloomberg estimate: Rs 14,900.9 crore) EBITDA fell 38% at Rs 3,070.2 crore Vs Rs 4,963.61 crore (Bloomberg estimate: Rs 3,854.4 crore) EBITDA margin 21.41% Vs 46.85% (Bloomberg estimate: 25.86%) Net profit up 3% at Rs 2,206.97 crore.

Delhivery Q4 FY22 (Consolidated, QoQ) Revenue up 4% at Rs 2,071.75 crore Vs Rs 1,995.04 crore EBIT fell 20% at negative Rs 159.32 crore Vs negative Rs 132.38 crore EBIT margin -7.69% Vs -6.64% Net loss fell 5% at Rs 119.86 crore Vs Rs 126.51 crore

Brokerage Radar:

CLSA ON JUBILANT FOODWORKS: Sell, TP Rs 500 4Q: better top-line but earnings in-line Aggressive store expansion plans Competition in pizza space is rising Rising mobility & competition could cause its gross margin to revert to its pre-Covid level of 75%.

MORGAN STANLEY ON GLENMARK PHARMA: UW, TP Cut to Rs 422 GNP’s core business is stabilizing with steady sales growth & margin consolidation. It is investing in its NCE portfolio, which is at a relatively nascent stage.

MORGAN STANLEY ON M&M: OW, TP raised to Rs 1198 Increases to tractor vol est drive F23 & F24 EPS upgrades With auto turnaround on track & group ROE improving, core biz at 13x F24 P/E looks attractive Capital allocation strategy working well – next focus on accelerating growth

International Markets:

U.S & Europe:

Particulars       30th  May    Chg Chg(%)
Nasdaq 12,131.13 390.48               3.33
Dow 33212.96 575.77      1.76
FTSE 7,600.06 14.6 0.19
CAC 6,562.39 46.64 0.72
DAX 14,575.98 113.79 0.79
Dow Fut.* 33234.40      – 77.4     -0.21

Asian markets:

Particulars    31st May    Chg. Chg(%)
SGX Nifty 16,490.00 153 0.94
Nikkei 27,309.35 527.67 1.97
Straits Times 3,238.54 7.99 0.25
Hang Seng 21,103.08 405.72 1.96
Shanghai 3,145.12 14.88 0.48

ADR Watch:

Particulars     30th May Chg. Chg.(%)
Dr Reddy 56.31 0 0
HDFC Bank 58.94 0 0
ICICI Bank 19.36 0 0
Infosys 19 0 0
Tata Motor 28.19 0 0
Wipro 6.1 0 0

Commodities & Currency:

Particulars Current Price Chg(%)
USD/INR 77.54 0.04
Brent 118.71 0.94
Gold 1855.33 -0.11
Silver 21.841 -0.59

FIIs & DII:

Particulars 30th May                           27th May
FIIs 502.08                       -1943.10                       
DIIs 1524.49 2727.47

News Update

Mahindra & Mahindra: The company sold 2.76% stake in TVS Automobile Solutions for Rs 45 crore.

MPS: The company completed acquisition of EI Designs through MPS Interactive Systems, its wholly owned subsidiary for Rs 40 crore.

Lemon Tree Hotels: The company has signed a license agreement for a 40 room hotel at Chirang, Assam under its brand ‘Keys Select, by Lemon Tree Hotels.’ The hotel is expected to be operational by June, 2026.

Source: Moneycontrol, Livemint,, Bloomberg, Investing

Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014

Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.
For analyst certification and other important disclosures, see the Disclosure Appendix, or go to www.elitewealth.in. Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)
Disclosure Appendix
Analyst Certification (For Reports)
Israil Khan, Elite Wealth Limited, suhail@elitewealth.in
The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.
As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:
(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.
For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
Research Excerpts
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit www.elitewealth.in.
Company-Specific Disclosures
Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting https://www.elitewealth.in, or emailing research@elitestock.com with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail research@elitestock.com.
Options related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at https://www.elitewealth.in
Other Disclosures
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.
Ownership and material conflicts of interest Disclosure
Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.
Country Specific Disclosures
India – For private circulation only, not for sale.
Legal Entities Disclosures
Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone:011-43035555, Facsimile: 011-22795783 and Website: www.elitewealth.in
EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:
1. Reports
a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
(b) EWL or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
(c) EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
2. Compensation
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
(c) EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(d) EWL or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(e) EWL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report.
3 In respect of Public Appearances
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL